CAMBRIDGE, Mass.–(Company WIRE)–Jan 14, 2021–
Amylyx Prescription drugs, Inc., a pharmaceutical company concentrated on establishing new remedies for amyotrophic lateral sclerosis (ALS), Alzheimer’s Disorder and other neurodegenerative ailments, today introduced the appointment of James Frates as Chief Economical Officer (CFO), effective Jan. 25, 2021. Mr. Frates joins Amylyx subsequent his tenure as CFO at Alkermes, considering the fact that 1998.
This push release characteristics multimedia. Check out the complete release listed here: https://www.businesswire.com/information/dwelling/20210114005141/en/
James Frates, Amylyx Chief Economic Officer (Picture: Enterprise Wire)
“We are so excited for Jim to be part of us at this significant juncture for Amylyx,” stated Joshua Cohen, Co-CEO, Chairman and Co-Founder of Amylyx. “Jim’s depth and breadth of encounter as a biopharmaceutical government coupled with his financial acumen and individual mission for bringing promising therapies to individuals with ALS make him a amazing addition to our management crew.”
“Jim brings the exclusive combination of encounter with growing biopharma providers focused on the central nervous program, equally as a CFO and a board member, and passion for the men and women we serve,” said Justin Klee, Co-CEO and Co-Founder of Amylyx. “Jim plainly embodies our values and we are thrilled to have him sign up for our mission.”
Frates is an seasoned leader who served as Alkermes CFO through its development from a clinical stage enterprise to an international business and progress organization with a number of goods, in excess of $1 billion in profits and about 2000 employees. Frates aided control the enterprise as a result of quite a few acquisitions and financings in the financial debt, fairness and non-public markets. Prior to Alkermes, Frates labored as an expenditure banker at Robertson, Stephens & Enterprise and Morgan Stanley. Frates now serves on the Board of Sage Therapeutics, Inc., The Roxbury Latin Faculty and St. Francis Dwelling in Boston. He is a graduate of Harvard Faculty and acquired an MBA from the Harvard Graduate School of Business enterprise Administration.
“Since my cousin Pete Frates was diagnosed with ALS in 2012, and by way of his remarkable perform with the Ice Bucket Problem, I have felt a calling to turn into additional concerned in the fight to come across far more effective treatment plans. I am eager to be a part of Amylyx mainly because it has created so a great deal development towards neurodegenerative health conditions,” explained Frates. “I believe my working experience can support the organization scale and produce on its promise of developing a medicine that can enable hold off neurodegeneration in clients. The prospect to support struggle ALS suggests a terrific offer to me and my family.”
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc. is a pharmaceutical corporation working on building a novel therapeutic for amyotrophic lateral sclerosis (ALS), Alzheimer’s disorder and other neurodegenerative health conditions. For much more information and facts, go to www.amylyx.com and adhere to us on LinkedIn and Twitter.
Perspective supply version on businesswire.com:https://www.businesswire.com/information/household/20210114005141/en/
Call: Merissa Muller
Finn Partners
(617) 778-6633
Merissa.Muller@finnpartners.com
Key phrase: MASSACHUSETTS UNITED STATES NORTH The usa
Industry Key word: BIOTECHNOLOGY Psychological Overall health OTHER Health Wellness PHARMACEUTICAL
Source: Amylyx Prescription drugs, Inc.
Copyright Company Wire 2021.
PUB: 01/14/2021 08:00 AM/DISC: 01/14/2021 08:01 AM
http://www.businesswire.com/news/residence/20210114005141/en